title: [Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis].
abstract: Pharmacokinetics and Tolerability of Telenzepine in Patients with Chronic Liver Diseases. The pharmacokinetics and tolerability of the new selective muscarinic M1-antagonist telenzepine (BY 803; CAS 80880-90-6) were studied in 10 patients with compensated liver cirrhosis who were treated over 4 weeks with 3 mg at night. 3 mg telenzepine was well tolerated. There was no deterioration of laboratory parameters during the 4 weeks treatment course. Following a single oral dose of 3 mg telenzepine the mean maximal plasma level (cmax) averaged 5.7 (1.9-10.1) ng/ml. After repeated dosing 3 patients displayed different kinetic behaviour resulting in higher values of AUC on day 14/15 in comparison to day 1/2. tmax and cmax remained unchanged. It can be concluded that even in patients with compensated liver cirrhosis no significant accumulation of the compound will occur.
authors.affiliation: Krankenhaus Schwetzingen, Medizinische Universitätsklinik Heidelberg.
authors.forename: A
authors.initials: A
authors.lastname: Reinicke
authors.forename: P
authors.initials: P
authors.lastname: Müller
authors.forename: H G
authors.initials: HG
authors.lastname: Dammann
authors.forename: B
authors.initials: B
authors.lastname: Simon
mesh_terms: D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D006207:Half-Life; D006801:Humans; D008103:Liver Cirrhosis / Q000378:metabolism*; D008875:Middle Aged; D010276:Parasympatholytics / Q000009:adverse effects / Q000493:pharmacokinetics*; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D010276:Parasympatholytics; C046338:telenzepine; D010890:Pirenzepine
vernacular_title: Pharmakokinetik und Verträglichkeit von Telenzepin bei Patienten mit kompensierter Leberzirrhose.